Oncothyreon, Inc. (NASDAQ: ONTY) is a biotechnology company dedicated to the development of oncology products that can improve the lives and outcomes of cancer patients. Recognizing that cancer is a complex disease involving changes to individual cells, the tumor microenvironment and the immune system, the company’s product pipeline reflects this complexity and includes small molecules designed to attack cancer cells directly and synthetic vaccines designed to stimulate an immune response against cancer cells (cancer immunotherapy). For more information, visit the company’s website atwww.oncothyreon.com.